On September 7, 2011, the U.S. Food and Drug Administration (FDA or Agency) approved a new animal drug application (NADA) for a product containing pergolide mesylate (NADA 141-331) marketed under the trade name Prascend Tablets for the control of the clinical signs associated with Cushing’s Disease in horses. Consistent with this approval, the Agency is announcing that it intends to consider the factors set forth in Compliance Policy Guide (CPG) Sec. 608.400 - Compounding of Drugs for Use in Animals (CPG 7125.40) in evaluating potential enforcement actions involving the compounding of pergolide products for animal use from bulk active pharmaceutical ingredient (API).
In the past, veterinarians prescribed human pergolide products to treat Cushing’s Disease in horses under the “extralabel” use provisions of the Federal Food, Drug, and Cosmetic Act. However, in May 2007, the human pergolide products were removed from the market due to concerns about cardiac side effects in humans. At that time FDA stated that it would work with the sponsors of approved human products and others to ensure that pergolide remained available to treat Cushing’s Syndrome in horses until a new animal drug application was approved for that use. FDA stated that this would include, among other things, exercising enforcement discretion as appropriate over the pharmacy compounding of pergolide for use in animals.
Consistent with our previous statement, based on the approval of Prascend, FDA intends to apply the Federal Food, Drug, and Cosmetic Act requirements regarding new animal drugs to animal drugs containing pergolide that are compounded from bulk API in accordance with CPG 608.400.
The preceding text is the message published today by the FDA.
In Monday's Federal Register, the change becomes official and the verbiage is a little more clear. It includes this summary statement:
SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an original new animal drug application (NADA) filed by Boehringer Ingelheim Vetmedica, Inc. The NADA provides for the veterinary prescription use of pergolide mesylate tablets in horses for the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease).
Download the full Federal Register documentation in PDF format.
Photo of pony with Cushings disease at top courtesy of University of Nottingham School of Veterinary Medicine and Science.
 |
| Order your copy of an extensive reference book on hoof rehabilitation. |
Follow Hoofcare + Lameness on Twitter: @HoofcareJournal
Read this blog's headlines on the Hoofcare + Lameness Facebook Page
Disclosure of Material Connection: I have not received any direct compensation for writing this post. I have no material connection to the brands, products, or services that I have mentioned, other than Hoofcare Publishing. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: Guides Concerning the Use of Endorsements and Testimonials in Advertising.
